Lenovo Announces New Innovations in Gaming, Software, Visuals, and Accessories for the Holidays
1.9.2023 07:20:00 EEST | Business Wire | Press release
Today, Lenovo announced several new products and solutions at its annual holiday product launch. The new additions to the portfolio – which include AI-tuned innovations in gaming, a groundbreaking 3D monitor, software solutions, versatile accessories, and more – are available to explore here.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831307965/en/
Lenovo Announces New Innovations in Gaming, Software, Visuals, and Accessories for the Holidays (Photo: Business Wire)
Gaming on the Go: Lenovo Legion™ Gaming Handheld Device and Accessories Untether PC Gaming
The new Lenovo Legion Go is the company’s first Windows gaming handheld device that gives gamers more freedom to game however—and wherever—they want. The Lenovo Legion Go is designed for gamers who will settle for nothing less than top-tier specs and visuals on their handheld device. Along with the new micro-OLED-equipped Lenovo Legion Glasses and new Lenovo Legion E510 7.1 RGB Gaming In-Ear Headphones, the debut of the Lenovo Legion Go is a marked expansion of the Lenovo Legion ecosystem of gaming devices, monitors, accessories, software, and services that empower gamers to immerse themselves in their games.
- The new Lenovo Legion Go brings Windows PC gaming power to a handheld mobile form factor, powered by AMD Ryzen™ Z1 Series processors that bring games to life on its 8.8-inch Lenovo PureSight Gaming Display.
- For gamers who want to take their Lenovo Legion Go portable gaming experience to the next level, the new Lenovo Legion Glasses leverage micro-OLED technology to provide a large screen viewing experience that fits in the pocket.
- For a truly immersive gaming experience, the new Lenovo Legion E510 7.1 RGB Gaming In-Ear Headphones offer hi-res 7.1 surround sound audio with a multifunction inline controller.
The King of Cool: Lenovo Legion 9i is the World’s First AI-Tuned Gaming Laptop with an Integrated Liquid-Cooling System1
The Lenovo Legion 9i (16”, 8) is the first top-of-the-line 16-inch gaming laptop in Lenovo Legion’s ecosystem—and in the world—with a self-contained liquid-cooling system1, designed for gamers and creators with heavy graphic workflow requirements who need a full development studio in their bag. The Lenovo Legion 9i leads the Lenovo Legion lineup that also includes the Lenovo Legion Pro series for competitive gamers and the Lenovo Legion Slim series for gamers who value agility, as well as Lenovo Legion displays and peripherals. Also announced today are the Lenovo Legion 16” Gaming Backpack GB700 and GB400, two backpack options that give gamers a choice between slim and lightweight agility or extra storage without sacrificing protection for their Lenovo Legion 9i (16”, 8) or any other laptops and accessories.
Transforming Digital Workspaces: New Devices and Software Power the Future of Hybrid Work
In addition to new gaming devices, Lenovo is unveiling new cutting-edge tech tools and essentials tailored to empower the dynamic, evolving needs of today's business end-users. Its new monitor, software, and accessories are not only designed to boost the capabilities of today’s remote and hybrid workforces, but also to address significant challenges faced by businesses as they digitize operations across departments. Lenovo research shows that managing a remote workforce and global teams remain central tasks for CIOs.2 That’s why the new offerings integrate impressive processing power, immersive 3D, and advanced security to create a unified, human-centered experience.
- For professional content creators who require immersive 3D visualization, the new ThinkVision™ 27 3D Monitor – a stunning 27-inch, glasses-free, 2D/3D compatible monitor – offers seamless 3D effects and real-time eye-tracking.
- The new Lenovo Wired VOIP Headset and Lenovo Wired ANC Headset Gen 2 are high-quality audio solutions for professionals in hybrid work environments, include an inline call control box, active noise cancellation with the latter, and compatibility with popular conferencing platforms.
- For remote work and to support sustainability efforts, the cloud-based Lenovo Device Manager will roll out enhanced new features that include a comprehensive AI-powered energy management solution that efficiently manages device fleets and optimizes power usage.
- To round out the new line-up are a selection of sophisticated and comfortable carry cases, the Lenovo ThinkPad Professional 16inch Backpack Gen 2, and the ThinkPad Professional 16inch and 14inch Topload Gen 2.
For specific details on all the new products and solutions, see the various releases linked below and the press kit on Lenovo StoryHub.
- The King of Cool: Lenovo Introduces the Legion 9i, the World’s First AI-Tuned Gaming Laptop with Integrated Liquid-Cooling System
- Gaming on the Go: Lenovo Unveils a New Legion Gaming Handheld Device and Accessories that Untether PC Gaming
- Transforming Digital Workspaces: Lenovo Unveils New Devices and Software to Power the Future of Hybrid Work
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
1Per an internal research conducted as of June 22, 2023, based on comparisons of gaming computers distributed by global PC manufacturers shipping > 1 million units worldwide annually, contained in a 16" panel size supported with a liquid cooling pump and does not have an external cooling attachment.
2 The Resilient CIO: Lenovo Global Study of CIOs 2023
LENOVO, LENOVO LEGION, and THINKVISION are trademarks of Lenovo. AMD and Ryzen are trademarks of Advanced Micro Devices. Inc. All other trademarks are the property of their respective owners. ©2023 Lenovo Group Limited
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831307965/en/
Contact information
Wendy Fung, wfung@lenovo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom